Co-Diagnostics, Inc. Issues Operational Update

by Co-Diagnostics | Sep 1, 2020 | Market Update, News Release

Salt Lake City, Utah – September 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, issued the following statement concerning the progress of the...

Co-Diagnostics, Inc. To Discuss Recent Company Growth and Upcoming Expansion Plans at H.C. Wainwright Global Investment Conference

by Co-Diagnostics | Aug 25, 2020 | News Release

Salt Lake City, Utah – August 25, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Company CEO Dwight Egan will be discussing the...

Co-Diagnostics, Inc. Receives Enhanced U.S. Patent Protection for CoPrimer™ Technology Used in COVID-19 Test

by Co-Diagnostics | Aug 20, 2020 | News Release

Salt Lake City, Utah – August 20, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that the United States Patent and Trademark Office has...

Co-Diagnostics, Inc. Announces Q2 2020 Results on Form 10-Q

by Co-Diagnostics | Aug 13, 2020 | News Release

Company reports robust sales of COVID-19 tests and net income per common share of $0.43 Salt Lake City, Utah – August 13, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of...

Co-Diagnostics, Inc. Announces Q2 2020 Earnings Release Date and Earnings Webcast

by Co-Diagnostics | Aug 11, 2020 | News Release

Salt Lake City, Utah – August 11, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will release its second quarter 2020 earnings...